XML 37 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Organization, Basis of Presentation and Liquidity (Tables)
12 Months Ended
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Ownership of Outstanding Shares of Its Subsidiaries

The following table reflects AgeX’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of December 31, 2020.

 

Subsidiary   Field of Business   AgeX Ownership     Country
ReCyte Therapeutics   Early stage pre-clinical research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, and ischemic conditions     94.8 %     USA
                 
LifeMap Sciences (1)   Biomedical, gene and disease databases and tools     80.7 %     USA

 

  (1) On March 15, 2021, LifeMap Sciences was acquired by a third party in a cash-out merger. LifeMap Sciences includes LifeMap Sciences, Inc. and its wholly-owned subsidiary LifeMap Sciences, Ltd. an Israeli company which has discontinued operations, and proceedings have been commenced to dissolve the Israeli subsidiary. (See Note 9)